Loading provider…
Loading provider…
Medical Oncology Physician in Los Angeles, CA
NPI: 1164448734Primary Employer
USC Care Medical Group, Inc
keckmedicine.org
HQ Phone
Get MD Mark's Phone Numberphone_androidMobile
Get MD Mark's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2020 - 2026
IL State Medical License
2004 - 2026
IL State Medical License
CA State Medical License

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Hematology

American Board of Internal Medicine
Medical Oncology

The Royal College of Physicians and Surgeons of Canada
Internal Medicine/Medical Oncology
University of Toronto
Fellowship • 2004 - 2006
2004 - 2006
Dalhousie University
Internship • 1998 - 1999
1998 - 1999
Residency • 1999 - 2001
1999 - 2001
University of Illinois College of Medicine at Chicago
Fellowship • Hematology and Medical Oncology
2001 - 2004
McGill University Faculty of Medicine
Medical School
Until 1998
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99215Established patient office or other outpatient, visit typically 40 minutes | 131 | 315 |
| 2 | 99214Established patient office or other outpatient visit, 30-39 minutes | 99 | 162 |
| 3 | 99205New patient office or other outpatient visit, typically 60 minutes | 52 | 52 |
Targeted therapies in bone sarcomas: current approach and future directions
Authors: Yarber, Jessica Lee, Agulnik, Mark
Journal: Expert Opin Investig Drugs
Publication Date: 2011-04-22
New developments in mammalian target of rapamycin inhibitors for the treatment of sarcoma.
Authors: @ValidYN, LastName, ForeName, Initials, AffiliationInfo
Journal: Cancer
Publication Date: 2011-08-11
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, PROCEDURE: Positron Emission Tomography, PROCEDURE: Biospecimen Collection, PROCEDURE: Computed Tomography, PROCEDURE: Biopsy Procedure, DRUG: Rogaratinib
Lead Sponsor: City of Hope Medical Center
Collaborators: National Cancer Institute (NCI)
Intervention / Treatment: OTHER: Questionnaire Administration, DRUG: Temozolomide, OTHER: Quality-of-Life Assessment, DRUG: Cabozantinib
Lead Sponsor: National Cancer Institute (NCI)
Intervention / Treatment: PROCEDURE: Magnetic Resonance Imaging, OTHER: Questionnaire Administration, BIOLOGICAL: Nivolumab, PROCEDURE: Biospecimen Collection, OTHER: Quality-of-Life Assessment, DRUG: Paclitaxel, PROCEDURE: Computed Tomography, DRUG: Cabozantinib S-malate, PROCEDURE: FDG-Positron Emission Tomography